Loading
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Regular session
$1.676
+$0.016 · +0.96%
Regular session · ET · Market data may be delayed.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Day range
Current $1.676
52-week range
Current $1.676
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
42
Fair Value
Sentiment
52
Mixed
Risk
75
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Day range
Current $1.676
52-week range
Current $1.676
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 893K USD | 76K USD | — | — | — |
| Gross profit | 893K USD | 76K USD | — | — | — |
| Research and development | 114.12M USD | 127.67M USD | 106.71M USD | 82.07M USD | 46.26M USD |
| Selling, general, and administrative | 51.78M USD | 56.08M USD | 44.82M USD | 70.94M USD | 8.86M USD |
| Operating expenses | 165.9M USD | 183.75M USD | 151.52M USD | 153.01M USD | 55.11M USD |
| Interest income | 13.81M USD | 19.75M USD | 22.08M USD | 5.98M USD | 2K USD |
| Interest expense | 4K USD | 9K USD | 12K USD | 215K USD | — |
| Depreciation and amortization | 6.58M USD | 5.43M USD | 3.85M USD | 3.04M USD | 1.98M USD |
| Operating income | −165.01M USD | −183.68M USD | −151.52M USD | −153.01M USD | −55.11M USD |
| Net income | −68.99M USD | −61.19M USD | −35.47M USD | −108.03M USD | −55.15M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM4.5M0.01%77.7B USD0.19%$278.26+0.25%
Vanguard Extended Market ETFVXF2.41M0.00%95.4B USD0.05%$234.06+0.40%
Schwab U.S. Small-Cap ETFSCHA1.32M0.01%21.73B USD0.03%$32.715+0.17%
iShares Russell 2000 Growth ETFIWO1.13M0.01%14.04B USD0.24%$355.18+0.48%
Vanguard Russell 2000 ETFVTWO817.69K0.00%18B USD0.06%$112.4+0.27%
Simplify Propel Opportunities ETFSURI803.01K1.07%74.84M USD2.82%$17.07+1.31%
iShares Micro-Cap ETFIWC566.91K0.04%1.32B USD0.60%$182.95+0.09%
iShares Russell 2000 Value ETFIWN502.54K—13.75B USD0.24%$210.84-0.05%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
